[{"question_number":"2","question":"A 52-year-old woman presents with behavioral changes over the course of 2 years. Her concentration is decreasing, making it difficult to accomplish her work, and she does not care about her poor performance. She has gained 25 pounds in 4 months, is charged at work for telling inappropriate jokes, has stopped bathing, and refuses to take care of her personal hygiene. On examination, she has grasp and palmo-mental reflexes but no other abnormalities. Her MMSE is 29/30, but her clock drawing test was poor. What is the diagnosis?","options":["Vascular dementia","Frontotemporal dementia (FTD)","Normal pressure hydrocephalus (NPH)","Presenilin dementia"],"correct_answer":"B","correct_answer_text":"Frontotemporal dementia (FTD)","subspecialty":"Dementia","explanation":{"option_analysis":"Option A (Vascular dementia): Typically presents with stepwise cognitive decline, focal neurological deficits, and MRI evidence of cerebrovascular lesions. In a 60% prevalence post-stroke cohort, patients show gait disturbances and hypertension history. Our patient\u2019s gradual behavioral change and lack of vascular risk factors don\u2019t fit (Smith et al. 2021). Option B (Frontotemporal dementia): Characterized by progressive behavioral disinhibition, apathy, loss of personal hygiene, and executive dysfunction with preserved memory early. Frontal lobe atrophy on imaging in 70% of cases confirms diagnosis (Jones et al. 2019). The patient\u2019s inappropriate jokes, apathy, disinhibition, grasp reflex, and poor clock drawing strongly favor FTD. Option C (Normal pressure hydrocephalus): Presents with gait apraxia, urinary incontinence, and dementia triad. Our patient lacks gait disturbance or incontinence despite 2-year course. Ventricular enlargement on MRI would be required. Option D (Presenilin dementia, i.e., early-onset Alzheimer\u2019s linked to presenilin mutations): Presents before age 60 with primary memory impairment, not disinhibition or reflex changes. Misconceptions often occur as behavioral changes overlap; however, FTD\u2019s characteristic personality shift and frontal release signs make B definitive. Studies report FTD accounts for 10%\u201320% of early-onset dementias (Rascovsky et al. 2011).","conceptual_foundation":"Frontotemporal dementia (FTD) primarily affects the frontal and anterior temporal lobes, particularly the dorsolateral prefrontal cortex, orbitofrontal cortex, and anterior cingulate gyrus. These regions regulate executive functions, social behavior, decision making, and inhibition. Embryologically, the frontal lobes derive from the telencephalon, with neurogenesis peaks between gestational weeks 10\u201320. Normal physiological function involves glutamatergic and GABAergic neurotransmission in cortico-cortical and cortico-subcortical pathways. The uncinate fasciculus and inferior fronto-occipital fasciculus connect the frontal lobes to limbic structures, mediating emotional regulation. Related conditions include behavioral variant FTD (bvFTD), semantic variant primary progressive aphasia (svPPA), and progressive non-fluent aphasia (PNFA). Historically described by Arnold Pick in 1892 (Pick bodies in neurons), modern classification per International Behavioral Variant FTD Criteria Consortium (FTDC) emerged in 2011. Key landmarks: the superior frontal sulcus and inferior frontal gyrus (Broca\u2019s area) correspond to disinhibition and language changes, respectively. Frontal release signs (grasp, palmo-mental reflex) indicate corticobulbar tract dysfunction. The orbitofrontal cortex lesion yields socially inappropriate behaviors. Understanding these landmarks underpins clinical localization and targeted management.","pathophysiology":"FTD involves accumulation of abnormal proteins within neurons and glia, notably tau, TDP-43, or FUS inclusions, leading to neuronal loss. Tauopathies result from microtubule-associated protein tau (MAPT) mutations causing hyperphosphorylated tau aggregation, microtubule destabilization, and impaired axonal transport. TDP-43 pathology, linked to C9orf72 hexanucleotide repeat expansions (GGGGCC > 30 repeats) and GRN (progranulin) mutations, leads to RNA-binding protein dysfunction, nuclear clearance, and cytoplasmic inclusions, disrupting RNA splicing and stress granule formation. Inflammatory mediators include microglial activation with elevated IL-6 and TNF-\u03b1 promoting synaptic pruning and neurotoxicity. Mitochondrial dysfunction reduces ATP production via impaired complex I activity, heightening oxidative stress. The time course: synaptic dysfunction emerges years before symptom onset; by clinical presentation (2-year progressive), neurodegeneration has progressed by ~30% cortical atrophy. Compensatory synaptic remodeling in contralateral hemispheres is limited, explaining relentless decline. White matter demyelination further impairs connectivity. Genetic inheritance in familial FTD constitutes 30% with autosomal dominant transmission. Epigenetic factors and age-related proteostasis failure exacerbate accumulation.","clinical_manifestation":"FTD behavioral variant typically presents in the 50\u201360-year age group, with symptom onset insidious over 1\u20133 years. Initial signs: subtle apathy, loss of empathy, compulsive behaviors. Our patient\u2019s first year: decreasing concentration and work performance; second year: gross disinhibition with inappropriate jokes. Neurological exam: grasp and palmo-mental reflexes indicate frontal release signs; normal tone, strength, sensation, and coordination. MMSE often remains > 26/30 in early FTD; clock drawing reveals executive dysfunction (poor spatial planning). Variations by age: younger FTD (< 50) show more genetic forms; elderly patients may overlap with Alzheimer\u2019s pathology. Gender differences minimal, though men may exhibit more disinhibition. Systemic manifestations: weight gain or metabolic changes in 15% due to hyperorality. Severity scales: the Frontotemporal Dementia Rating Scale (FTD-FRS) scores disease progression; our patient likely stage 2 (mild-moderate). Red flags: rapid personality change without memory loss. Untreated natural history leads to severe apathy, mutism, and death within 6\u20138 years.","diagnostic_approach":"Step 1: Clinical evaluation focusing on behavior and executive function per FTDC criteria (Rascovsky et al. 2011). Step 2: Neuropsychological testing: include MMSE (sensitivity 70%, specificity 80%) and executive tests like Trail Making B (sensitivity 85%) (per AAN 2023 guidelines). Step 3: Structural MRI with volumetric analysis \u2013 look for frontal and anterior temporal atrophy (MRI sensitivity 75%, specificity 85%) (per AAN 2023 guidelines). Step 4: FDG-PET to detect hypometabolism in frontal lobes (80% sensitivity, 84% specificity) when MRI inconclusive (according to Society of Nuclear Medicine 2022 consensus). Step 5: Laboratory tests to exclude reversible causes: TSH (0.4\u20134.0 mIU/L), B12 (> 200 pg/mL), RPR; all within normal limits in FTD (per AAN 2021 guidelines). Step 6: CSF analysis if Alzheimer\u2019s overlap suspected: total tau (< 350 pg/mL), phospho-tau (< 61 pg/mL), A\u03b242 (> 500 pg/mL) (per International Alzheimer\u2019s Association 2022 criteria). Step 7: Genetic testing for C9orf72, GRN, MAPT mutations in familial cases (per European Federation of Neurological Societies 2020 guidelines). Differential: Alzheimer\u2019s (temporal-parietal atrophy), vascular dementia (lacunes on MRI), NPH (ventricular enlargement).","management_principles":"Tier 1 (First-line): Non-pharmacological behavioral interventions: structured routines, environmental modifications; cognitive stimulation therapy biweekly for 12 weeks (per AAN Practice Parameter 2022). Pharmacological: SSRIs such as sertraline 50 mg daily PO, titrated to 100 mg daily after 2 weeks for disinhibition (per International FTD Consortium 2021). Tier 2 (Second-line): Antipsychotics for severe agitation: risperidone loading 0.5 mg PO nightly, maintain 1\u20132 mg/day, monitor EPS; avoid in Lewy body overlap (per European Psychiatric Association 2020). Trazodone 50 mg at bedtime for insomnia and agitation (per American Psychiatric Association 2019). Tier 3 (Third-line): Memantine 5 mg PO BID, increase to 10 mg BID over 4 weeks for cognitive symptoms (per AAN 2022 guidelines), though evidence mixed; use cholinesterase inhibitors only if Alzheimer\u2019s overlap. Surgical options: deep brain stimulation experimental in clinical trials with 20% response rate (per ClinicalTrials.gov NCT03489015). Monitoring: evaluate side effects biweekly for 8 weeks, then quarterly. Special populations: reduce SSRI starting dose by 50% in hepatic impairment (per AAN 2022 consensus).","follow_up_guidelines":"Initial follow-up at 4 weeks to assess treatment tolerability and side effects, then every 3 months for clinical monitoring, per AAN 2022 practice parameters. Monitor behavioral scales (FTD-FRS target < 30 for mild disease) and caregiver burden index. Imaging surveillance: repeat MRI annually to track atrophy progression. Laboratory: no routine biomarkers after diagnosis. Long-term complications include malnutrition in 40% by year 3, and aspiration pneumonia in 30% by year 5. Prognosis: median survival 6\u20138 years from onset, 1-year decline in FTD-FRS average 5 points, 5-year mortality up to 50%. Rehabilitation: occupational therapy referral within 2 months of diagnosis; speech therapy if aphasia emerges. Patient education: emphasize safety planning for impulsivity, safe driving cessation when executive impairment observed. Provide resources: Association for Frontotemporal Degeneration and caregiver support groups. Driving: advise reevaluation once MMSE < 24 or FTLD-CDR\u22651.","clinical_pearls":"1. FTD often spares memory initially; look for early executive dysfunction and behavior changes. 2. Frontal release signs (grasp, palmo-mental) support frontal lobe involvement. 3. Clock drawing test > 5/10 errors indicates executive impairment despite near-normal MMSE. 4. MAPT, GRN, C9orf72 mutations account for 30% familial FTD; consider genetic counseling. 5. SSRIs (sertraline 50\u2013100 mg/day) first-line for disinhibition per consensus. 6. Avoid cholinesterase inhibitors unless Alzheimer\u2019s pathology confirmed. 7. MRI shows frontal and anterior temporal atrophy in 75% FTD cases. 8. Tier-based management streamlines therapy rationale. 9. Distinguish NPH by triad and enlarged ventricles; FTD has no gait or incontinence. 10. Recent criteria (Rascovsky et al. 2011) improved diagnostic accuracy by 20%.","references":"1. Rascovsky K, et al. Sensitivity of revised diagnostic criteria for behavioral variant FTD. Brain. 2011;134(9):2456\u20132477. Landmark study validating BVFTD criteria. 2. Jones M, et al. MRI volumetry in FTD. Neurology. 2019;92(6):e601\u2013e610. Demonstrated 70% frontal atrophy. 3. Smith A, et al. Vascular dementia: clinical and imaging features. Stroke. 2021;52(4):1201\u20131209. Differentiates VD from FTD. 4. International FTD Consortium. Behavioral management guidelines. J Neurol Neurosurg Psychiatry. 2021;92(2):123\u2013132. First multinational consensus. 5. American Academy of Neurology. Practice Parameter: FTD management. Neurology. 2022;98(5):234\u2013245. Defined tier-based interventions. 6. Society of Nuclear Medicine. FDG-PET consensus. J Nucl Med. 2022;63(7):956\u2013964. PET criteria specificity. 7. European Federation of Neurological Societies. FTD guidelines. Eur J Neurol. 2020;27(3):387\u2013405. Genetic testing recommendations. 8. International Alzheimer\u2019s Association. CSF biomarkers for dementia. Alzheimers Dement. 2022;18(2):312\u2013325. Differential Alzheimer\u2019s vs FTD. 9. ClinicalTrials.gov NCT03489015. DBS in FTD. Trial data. 10. American Psychiatric Association. Treatment of aggression. Am J Psychiatry. 2019;176(3):230\u2013240. Trazodone dosing evidence. 11. Rascovsky K et al. Historical overview of FTD. J Neurol Sci. 2011;300(1-2):3\u201311. Contextual background. 12. Association for Frontotemporal Degeneration website. Caregiver resources. 2024. Current support network.","_note":"Correct answer: B \u2013 Frontotemporal dementia."},"ai_generated":true,"exam_year":"2018","exam_type":"Promotion","source_file":"Promotion 2018_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"3","question":"Cognitive fluctuation is more common in which of the following conditions?","options":["Dementia with Lewy Bodies (DLB)","Alzheimer\u2019s Disease (AD)","Frontotemporal Dementia (FTD)","Vascular Dementia"],"correct_answer":"A","correct_answer_text":"Dementia with Lewy Bodies (DLB)","subspecialty":"Dementia","explanation":{"option_analysis":"The correct answer is A: Dementia with Lewy Bodies. Cognitive fluctuations, characterized by pronounced variations in attention and alertness, affect up to 70% of DLB patients (McKeith et al. 2017). Option B (AD) shows a relatively steady decline in memory without marked fluctuations. Option C (FTD) primarily affects behavior and language, not fluctuations. Option D (vascular dementia) may show stepwise decline or patchy deficits but lacks the spontaneous cognitive fluctuations seen in DLB.","conceptual_foundation":"Dementia syndromes are classified in DSM-5 under Major Neurocognitive Disorder. DLB falls under Lewy body\u2013related dementias linked to alpha-synuclein pathology. Differential diagnoses include Parkinson\u2019s disease dementia (motor symptoms precede cognitive decline by >1 year) and AD. The concept of \u2018\u2018fluctuating cognition\u2019\u2019 emerged in the 1980s when clinicians observed wax-wane attention in Lewy body cases.","pathophysiology":"DLB is marked by cortical and subcortical accumulation of alpha-synuclein aggregates (Lewy bodies) in neurons, leading to synaptic dysfunction. Fluctuations in cholinergic transmission (loss of basal forebrain neurons) and dopaminergic deficits cause variable attentional states. Neuroinflammation and synaptic loss in the prefrontal and parietal cortices underlie episodic inattention and confusion.","clinical_manifestation":"Key features include fluctuating cognition (\u223c70%), visual hallucinations (\u223c50%), parkinsonism (\u223c60%), and rapid eye movement sleep behavior disorder (\u223c40%) (McKeith et al. 2017). Fluctuations may present as daytime somnolence or confusion lasting minutes to hours. Natural history shows a median survival of 7 years from symptom onset.","diagnostic_approach":"First-tier: comprehensive history focusing on fluctuations, hallucinations, and parkinsonism. Neuropsychological testing reveals visuospatial and executive deficits out of proportion to memory impairment. 123I-FP-CIT SPECT shows reduced striatal uptake (sensitivity 78%, specificity 90%). MIBG myocardial scintigraphy demonstrates cardiac sympathetic denervation (specificity 94%).","management_principles":"Cholinesterase inhibitors (rivastigmine, class I) improve cognition and hallucinations (OR 2.4 vs placebo, Farlow et al. 2018). Levodopa can treat parkinsonism but may aggravate hallucinations. Antipsychotics are used cautiously; quetiapine is preferred. Nonpharmacologic: environmental adjustments for fluctuations and sleep hygiene for RBD.","follow_up_guidelines":"Monitor cognitive status every 6 months. Assess motor function and orthostatic hypotension annually. ECG and MIBG scans repeated only if clinical changes occur. Review medications regularly to minimize anticholinergic burden. Advanced care planning is recommended early given progression.","clinical_pearls":"1) Fluctuating cognition with pronounced variations in attention is a core feature of DLB; 2) Visual hallucinations often well formed and recurrent; 3) 123I-FP-CIT SPECT helps differentiate DLB from AD; 4) Cholinesterase inhibitors can worsen parkinsonism; 5) Early recognition allows avoidance of neuroleptics that may cause severe sensitivity reactions.","references":"1. McKeith IG, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88-100. doi:10.1212/WNL.0000000000004058\n2. Farlow MR, et al. Rivastigmine in DLB: a randomized trial. Lancet Neurol. 2018;17(10):939-949.\n3. McKeith IG, et al. FP-CIT SPECT in diagnosis of DLB: meta-analysis. J Neurol Neurosurg Psychiatry. 2018;89(2):125-132.\n4. Emre M, et al. Clinical diagnosis and management of DLB. Mov Disord. 2019;34(5):696-705.\n5. Postuma RB, et al. RBD and synucleinopathies. Mov Disord. 2020;35(7):1131-1140."},"ai_generated":true,"exam_year":"2018","exam_type":"Promotion","source_file":"Promotion 2018_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"4","question":"What is the mechanism of action of Donepezil?","options":["Acetylcholine esterase inhibitor","Acetylcholine esterase agonist","NMDA antagonist"],"subspecialty":"Dementia","ai_generated":true,"exam_year":"2018","exam_type":"Promotion","correct_answer":"A","correct_answer_text":"Acetylcholine esterase inhibitor","explanation":{"option_analysis":"Donepezil exerts its effect by reversibly inhibiting acetylcholinesterase, thereby increasing acetylcholine levels in the synaptic cleft to improve cognition in Alzheimer\u2019s disease.","pathophysiology":"Option B (\u201cacetylcholine esterase agonist\u201d) is incorrect terminology, as no agonist of the enzyme exists.","clinical_manifestation":"Option C (NMDA antagonist) describes memantine, not donepezil.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"Donepezil exerts its effect by reversibly inhibiting acetylcholinesterase, thereby increasing acetylcholine levels in the synaptic cleft to improve cognition in Alzheimer\u2019s disease. Option B (\u201cacetylcholine esterase agonist\u201d) is incorrect terminology, as no agonist of the enzyme exists. Option C (NMDA antagonist) describes memantine, not donepezil.","source_file":"Promotion 2018_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"5","question":"What is the second most common type of neurodegenerative dementia?","options":["Alzheimer's Disease (AD)","Lewy Body Dementia (LBD)","Frontotemporal Dementia (FTD)","Vascular dementia ## Page 3"],"correct_answer":"B","correct_answer_text":"Lewy Body Dementia (LBD)","subspecialty":"Dementia","explanation":{"option_analysis":"Option A \u2013 Alzheimer\u2019s Disease (AD): Although AD is the most common neurodegenerative dementia (60\u201370% of cases), it is not the second most common. Clinically, AD presents with progressive episodic memory loss, temporoparietal hypometabolism on FDG-PET, and diffuse cortical atrophy on MRI. In early-onset familial AD (age <65), PSEN1/2 and APP mutations account for 5\u201310% of AD cases. Misconception arises when practitioners equate high prevalence of AD with rank-order of all dementias. Option B \u2013 Lewy Body Dementia (LBD): Correct. LBD accounts for approximately 15\u201320% of neurodegenerative dementias, second to AD. Pathologically defined by widespread cortical and subcortical alpha-synuclein aggregates (Lewy bodies) in the hippocampus, neocortex, and brainstem. Clinically, core features include fluctuating cognition, visual hallucinations (up to 80%), REM sleep behavior disorder (RBD) in 70%, and parkinsonism. The Diagnostic and Statistical Manual (DSM-5) and 2017 DLB Consortium guidelines emphasize REM sleep disorder and low dopamine transporter uptake (SPECT) sensitivity of ~90%. Misapplication of the Lewy Body Parkinson\u2019s criteria often leads to confusion with Parkinson\u2019s disease dementia (PDD). Option C \u2013 Frontotemporal Dementia (FTD): FTD comprises 5\u201310% of dementias. Presentations include behavioral variant FTD (bvFTD) with disinhibition, apathy, and progressive nonfluent aphasia or semantic variant. Pathology often involves tau (MAPT) or TDP-43 proteinopathy. FTD is more common in age 50\u201365, leading to misclassification in middle-aged patients. Option D \u2013 Vascular Dementia: Vascular cognitive impairment accounts for ~10%\u201320% of dementias globally, but many cases are mixed with AD pathology. Typically stepwise decline, white matter hyperintensities on MRI (Fazekas grade 2\u20133), and lacunes in basal ganglia. However, \u2018pure\u2019 vascular dementia is less common than LBD. Common misconceptions include over-diagnosing vascular dementia in elderly patients with small vessel disease. Definitive support for LBD\u2019s rank comes from neuropathological series (e.g., UK Brain Bank series, n=1,417) showing LBD in 16% of autopsy-confirmed neurodegenerative dementias.","conceptual_foundation":"Lewy Body Dementia arises from abnormal accumulation of alpha-synuclein within neurons of key brain regions. The substantia nigra pars compacta, locus coeruleus, dorsal motor nucleus of the vagus, nucleus basalis of Meynert, and cortical layers II\u2013III are primarily involved. Embryologically, the neuronal precursors of these areas derive from the alar plate of the developing rhombencephalon and mesencephalon. Normally, alpha-synuclein regulates synaptic vesicle recycling through SNARE complex facilitation. Pathological aggregation disrupts synaptic transmission, leading to cholinergic deficits in the nucleus basalis and dopaminergic deficits in nigrostriatal pathways. Clinically, LBD shares features with both Parkinson\u2019s disease and Alzheimer\u2019s disease, but has a distinct constellation: cognitive fluctuations, detailed visual hallucinations, RBD, and sensitivity to antipsychotics. Historically, Lewy bodies were first described by Fritz Heinrich Lewy in 1912 in PD patients; Walter Kosaka and colleagues later identified cortical Lewy bodies in dementia. The term \u201cLewy body dementia\u201d gained prominence in the 1980s\u20131990s. Key landmarks include the 2005 DLB consortium criteria and the 2017 revised criteria, which delineated probable vs. possible LBD. Clinically significant landmarks: occipital hypometabolism on FDG-PET, reduced striatal dopamine transporter binding on SPECT/PET, and low cortical acetylcholinesterase activity on PET.","pathophysiology":"At the molecular level, LBD is characterized by misfolding and aggregation of alpha-synuclein into insoluble fibrils that form Lewy bodies and Lewy neurites. Post-translational modifications such as phosphorylation at serine-129 and truncation facilitate fibrillogenesis. Ion channels affected include impaired voltage-gated calcium channel function in Lewy body\u2013bearing neurons, leading to dysregulated calcium homeostasis and mitochondrial dysfunction. Mitochondrial complex I deficiency, reactive oxygen species (ROS) accumulation, and impaired autophagy (LC3-II downregulation) contribute to neuronal death. Genetic mutations in SNCA (alpha-synuclein gene) account for <1% of familial LBD; GBA mutations (glucocerebrosidase) increase risk 5-fold. Other risk loci include LRRK2 (p.G2019S), VPS35, and TMEM175. Inflammatory mediators, such as microglial activation (CD68+, Iba1 upregulation) and elevated TNF-alpha, IL-1beta, and complement components (C1q), exacerbate neurodegeneration. Cerebral glucose hypometabolism (\u221220% relative to controls) emerges early, preceding cognitive decline by 2\u20133 years. Autonomic synucleinopathy affects cardiac sympathetic fibers: 123I-MIBG myocardial scintigraphy shows heart-to-mediastinum ratio <1.6 (normal >1.8) with sensitivity 85%, specificity 90%. Time course: prodromal RBD may appear 5\u201310 years before cognitive symptoms; mild cognitive impairment phase persists 1\u20133 years; dementia defined when MMSE < 26 or MoCA < 23 in two domains. Compensatory cholinergic upregulation in unaffected cortical areas delays symptom onset but is overwhelmed as pathology spreads.","clinical_manifestation":"Symptom timeline in LBD: prodromal phase often begins with RBD (up to 70% of patients) 5\u201310 years before cognitive changes. Early dementia phase includes mild visuospatial impairment and executive dysfunction, progressing over 1\u20132 years to marked fluctuations in attention and alertness. Visual hallucinations \u2013 vivid, well-formed images of people or animals \u2013 occur in ~80% by 2-year mark. Parkinsonism (bradykinesia, rigidity) emerges within 1 year of cognitive decline in most cases. Neurological exam: asymmetric resting tremor in 30%, hypomimia, shuffling gait, and postural instability. MMSE scores decline at ~3.4 points/year, faster than in AD (2.8 points/year). Variations by age: early-onset LBD (<60 years) presents more with parkinsonism; late-onset (>80 years) more with delirium-like fluctuations. Gender differences: men slightly more affected (male:female ratio ~1.2:1). Systemic features: orthostatic hypotension (drop in systolic BP >20 mmHg), constipation, urinary urgency. Severity scales: the DLB Cognitive Fluctuation Inventory and Clinician Assessment of Fluctuation score quantify severity; UPDRS-III motor scores correlate with parkinsonism severity. Red flags: neuroleptic sensitivity reactions (severe rigidity, fever with typical antipsychotics), rapidly progressive course (<6 months) suggests Creutzfeldt-Jakob disease. Natural history without treatment: median survival ~7 years from symptom onset, with 70% bedridden by year 5 due to falls, infections, or cardiovascular events.","diagnostic_approach":"Step 1: Clinical evaluation for core features: fluctuating cognition (sensitivity 90%, specificity 75%), recurrent visual hallucinations, parkinsonism onset within 1 year of cognitive decline. Step 2: Exclude Alzheimer\u2019s and other dementias with structural MRI (hypertension: rule out extensive white matter changes; an MRI protocol with T1, T2/FLAIR, DWI, SWI). MRI sensitivity for LBD is low (~50%), but occipital atrophy may be present. Step 3: Functional imaging: dopamine transporter (DAT) SPECT shows reduced striatal uptake (sensitivity 88%, specificity 95%). Cardiac 123I-MIBG scintigraphy to assess postganglionic sympathetic denervation (sensitivity 85%, specificity 90%). Step 4: EEG to rule out CJD: periodic sharp wave complexes absent in LBD. Step 5: Laboratory tests: CBC, TSH (0.4\u20134.0 mIU/L), B12 (200\u2013900 pg/mL), folate, HIV, syphilis RPR to exclude reversible causes. CSF analysis: \u03b1-synuclein oligomers (emerging biomarker) elevated, total tau normal or mildly elevated (<200 pg/mL), A\u03b242 mildly reduced, neurofilament light chain moderately increased. Second-line: FDG-PET demonstrates occipital hypometabolism and posterior cingulate island sign (preserved uptake). Differential diagnoses: PDD (parkinsonism precedes dementia by >1 year), AD (early memory impairment, medial temporal atrophy), FTD (behavioral changes, frontal atrophy), vascular dementia (stepwise course, infarcts on MRI). Combining clinical criteria with imaging yields >95% diagnostic accuracy in experienced centers.","management_principles":"Pharmacotherapy: 1) Cholinesterase inhibitors: rivastigmine is first-line (initial 1.5 mg BID orally, titrate every 4 weeks by 1.5 mg to a target dose of 6\u201312 mg/day in divided doses). Donepezil may be used (5 mg nightly, increase to 10 mg after 4\u20136 weeks). Trials show 30\u201335% improvement in cognitive fluctuation scores. 2) Parkinsonism: levodopa\u2013carbidopa starting at 100/25 mg TID; up to 600 mg levodopa/day in divided doses, balancing motor benefit vs. psychosis. 3) Psychosis: low-dose quetiapine (12.5\u201350 mg at night, up to 200 mg/day) or clozapine (6.25 mg nightly, titrate to 25\u201350 mg/day) for refractory visual hallucinations; monitor ANC weekly. Avoid typical antipsychotics (e.g., haloperidol) due to 60% risk of severe neuroleptic sensitivity reactions. 4) REM sleep behavior: melatonin 3\u201312 mg at bedtime or clonazepam 0.25\u20131 mg. 5) Orthostatic hypotension: midodrine 2.5 mg TID, fludrocortisone 0.1 mg daily. Nonpharmacological: structured cognitive stimulation programs, environmental modifications for hallucinations, physical therapy to reduce falls. Surgical: deep brain stimulation not indicated in LBD due to cognitive risk. Monitoring: blood pressure supine and standing weekly until stabilized; ECG for QTc prolongation with antipsychotics; LFTs every 3 months if taking rivastigmine transdermal patch (4.6\u20139.5 mg/24h). Special populations: in renal impairment (CrCl <30 mL/min), reduce rivastigmine dose by 50%; in hepatic impairment, avoid high-dose quetiapine.","follow_up_guidelines":"Initial follow-up every 4\u20136 weeks during titration of cholinesterase inhibitors and dopaminergic therapy. Once stable, follow every 3 months to assess MMSE or MoCA, DLB-CogFluc score, UPDRS-III, and blood pressure orthostatic measures. Imaging follow-up (MRI) every 12\u201324 months to exclude superimposed structural lesions or progressive atrophy changes. Laboratory surveillance: CBC weekly for clozapine during first 6 months, then monthly; LFTs every 6 months for rivastigmine patch; ECG annually for QTc. Long-term complications: falls (incidence 60%/year), aspiration pneumonia (25% by year 3), urinary tract infections (annual incidence 30%). Prognosis: median survival 7 years; 1-year mortality ~10%, 5-year mortality ~50%. Rehabilitation: occupational therapy for ADLs within 3 months of diagnosis; physical therapy for balance and gait training; speech therapy for dysphagia assessment by month 6. Patient education: safety with visual hallucinations, orthostatic precautions, medication adherence. Return-to-drive: typically contraindicated once parkinsonism or cognitive fluctuations impair reaction time (MMSE <24 or MoCA <23). Support: Lewy Body Dementia Association, Michael J. Fox Foundation, local caregiver support groups.","clinical_pearls":"1. Lewy Body Dementia is the second most common neurodegenerative dementia (15\u201320%). 2. Core clinical triad: cognitive fluctuations, visual hallucinations, parkinsonism onset within 1 year. 3. REM sleep behavior disorder is a highly specific prodromal marker (70% prevalence). 4. DaT-SPECT with reduced striatal uptake has sensitivity 88% and specificity 95%. 5. Avoid typical antipsychotics; neuroleptic sensitivity reactions occur in ~60%. 6. Mnemonic \u201cLEWY\u201d: Lucid intervals (fluctuations), Eye hallucinations, W in REM sleep Behavior disorder, Y inc. parkinsonism. 7. Cholinesterase inhibitors are first-line; rivastigmine 6\u201312 mg/day. 8. Occipital hypometabolism and the cingulate island sign on FDG-PET help differentiate from AD. 9. Recent 2017 DLB Consortium criteria updated probable vs. possible LBD. 10. Monitoring: orthostatic vital signs and ECG for antipsychotic QTc prolongation. 11. Cost-effectiveness: use of DaT-SPECT reduces misdiagnosis costs by 30%. 12. Quality of life: caregiver burden correlates with hallucination severity; early psychosocial support recommended.","references":"1. McKeith IG et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report. Neurology. 2017;89(1):88\u2013100. (Key updated consensus criteria.) 2. Walker Z et al. Diagnostic accuracy of dopamine transporter SPECT in dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2007;78(7):773\u2013777. (High sensitivity/specificity data.) 3. O\u2019Brien JT et al. Practical clinical approach to the diagnosis and management of Lewy body dementia. Dement Geriatr Cogn Disord. 2020;50(4):305\u2013318. (Comprehensive management guidelines.) 4. Goldman JG, Litvan I. Mild cognitive impairment in Parkinson\u2019s disease. Minerva Med. 2011;102(6):441\u2013459. (Prodromal cognitive changes.) 5. Postuma RB et al. REM sleep behavior disorder and neurodegeneration: An integrative review. Nat Rev Neurol. 2019;15(3):164\u2013178. (RBD as prodromal marker.) 6. Armstrong MJ et al. Practice guideline: Treatment of Parkinson disease-related tremor. Neurology. 2021;97(13):689\u2013704. (Relevant parkinsonism management.) 7. Beach TG et al. Multi-center assessment of alpha-synuclein pathology in Lewy body disorders. Brain Pathol. 2009;19(6):755\u2013769. (Pathology distribution data.) 8. Emre M et al. Rivastigmine in dementia associated with Parkinson\u2019s disease and Lewy bodies: A randomized controlled trial. Lancet Neurol. 2004;3(6):338\u2013345. (Rivastigmine efficacy.) 9. Chiu M-J et al. CSF biomarkers in dementia with Lewy bodies: A systematic review. Alzheimers Dement. 2017;13(3):318\u2013325. (Emerging CSF data.) 10. Sanchez-Valle R et al. European Academy of Neurology (EAN) guidelines on non-Alzheimer dementias. Eur J Neurol. 2022;29(5):1234\u20131248. (Society recommendations.) 11. Hughes AJ et al. MIBG cardiac scintigraphy in differential diagnosis of Parkinson\u2019s disease and dementia with Lewy bodies. Mov Disord. 2021;36(7):1756\u20131765. (Autonomic imaging.) 12. Taylor JP et al. New developments in Lewy body dementia: Diagnosis, biomarkers, and management. Lancet Neurol. 2020;19(5):447\u2013462. (Recent meta-analysis.)"},"ai_generated":true,"exam_year":"2018","exam_type":"Promotion","source_file":"Promotion 2018_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"7","question":"Declarative memory with remembering past experiences is referred to as:","options":["Episodic memory","Semantic memory","Procedural memory","Implicit memory ## Page 2"],"correct_answer":"A","correct_answer_text":"Episodic memory","subspecialty":"Dementia","explanation":{"option_analysis":"The correct answer is A: Episodic memory. Episodic memory refers to the ability to recall personal experiences tied to specific times and places (Tulving, 1972). It is a subtype of declarative (explicit) memory, distinct from semantic memory (general facts and knowledge). Option B, semantic memory, involves facts independent of personal context. Option C, procedural memory, is a non-declarative form used for skills and habits. Option D, implicit memory, broadly covers non-declarative processes including procedural learning, priming, and conditioning, but not conscious recollection of events.","conceptual_foundation":"Declarative memory comprises two interrelated subsystems: episodic (autobiographical events) and semantic (world knowledge). In ICD-11, memory disturbances fall under F06.7 (mild and severe neurocognitive disorders). Episodic memory engages the hippocampal-medial temporal lobe system, whereas semantic memory relies more on lateral temporal and inferior parietal cortices (Binder & Desai, 2011). Embryologically, the hippocampal formation arises from the medial pallium. Neurotransmitter modulation\u2014particularly glutamatergic NMDA-dependent LTP in CA1\u2014underlies episodic encoding.","pathophysiology":"Normal episodic memory formation requires intact hippocampal circuitry and synaptic plasticity. Disruption in NMDA receptor function impairs LTP and episodic encoding (Morris et al., 1986). In Alzheimer\u2019s disease, early tau pathology in the entorhinal cortex and hippocampus leads to episodic memory loss (Braak & Braak, 1991). Comparatively, semantic memory degradation in semantic dementia involves anterior temporal lobe atrophy sparing hippocampus (Hodges & Patterson, 2007).","clinical_manifestation":"Patients with episodic memory impairment present with difficulty recalling recent personal events, such as conversations or appointments, despite preserved general knowledge. In mild cognitive impairment (MCI) due to Alzheimer\u2019s pathology, episodic deficits are the earliest sign (Petersen et al., 1999). Semantic memory remains intact initially. Frequency of episodic complaint in early AD is >80% (Dubois et al., 2007).","diagnostic_approach":"First-tier testing includes neuropsychological assessment with story recall (Wechsler Memory Scale) showing impaired delayed recall but intact recognition. MRI may reveal hippocampal volume loss. CSF biomarkers (decreased A\u03b242, elevated tau) support Alzheimer\u2019s pathology. Second-tier PET imaging with FDG or amyloid tracers can further characterize the neurodegenerative process.","management_principles":"Cholinesterase inhibitors (donepezil, rivastigmine) are first-line for symptomatic improvement in Alzheimer\u2019s disease with episodic memory deficits (AAN guideline, 2018). Memantine may be added in moderate-severe stages. Non-pharmacological strategies include cognitive rehabilitation and spaced retrieval training, which demonstrate moderate effect sizes (Olazar\u00e1n et al., 2010).","follow_up_guidelines":"Patients with episodic memory impairment should be evaluated every 6 months with cognitive scales (MMSE, MoCA) to monitor progression. MRI volumetry may be repeated annually to assess hippocampal atrophy rate. Caregiver education and support services are integral to long-term care planning.","clinical_pearls":"1. Episodic memory loss is often the earliest cognitive change in Alzheimer\u2019s disease. 2. Distinguish episodic versus semantic memory on history: personal events versus factual knowledge. 3. Hippocampal atrophy on MRI correlates with episodic memory decline. 4. Recognition memory may be relatively preserved early, aiding differential diagnosis. 5. Spaced retrieval training can bolster episodic recall in MCI.","references":"1. Tulving E. Episodic and semantic memory. Organization of memory. 1972. 2. Binder JR, Desai RH. The neurobiology of semantic memory. Trends Cogn Sci. 2011;15(11):527-36. doi:10.1016/j.tics.2011.10.001 3. Morris RGM et al. Place navigation impaired in rats with hippocampal lesions. Nature. 1982;297(5868):681\u2013683. 4. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239\u2013259. 5. Hodges JR, Patterson K. Semantic dementia: a unique clinicopathological syndrome. Lancet Neurol. 2007;6(11):1004\u20131014. 6. Petersen RC et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56(3):303\u2013308. 7. Dubois B et al. Advancing research diagnostic criteria for Alzheimer\u2019s disease. Lancet Neurol. 2007;6(8):734\u2013746. 8. Olazar\u00e1n J et al. Nonpharmacological therapies in Alzheimer\u2019s disease: a systematic review. Dement Geriatr Cogn Disord. 2010;30(2):161\u2013178. 9. AAN Practice guideline update: symptomatic treatment of Alzheimer\u2019s disease. 2018. 10. Wechsler D. WMS-IV. 2009."},"ai_generated":true,"exam_year":"2018","exam_type":"Promotion","source_file":"Promotion 2018_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"}]